Available studies have shown that Mir22hg plays a cancer inhibitory role in gastric cancer (Li and Wang 2019), hepatocellular carcinoma (Su et al. 2018), lung cancer (Wang et al. 2023a, b), and colorectal cancer (Xu et al. 2020), whereas it promotes tumor progression in esophageal cancer (Su et al. 2019). This evidence concerns the gene MIR22HG and esophageal cancer.